Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program

被引：32

作者：

Jacot, William ^{[1
,2
]}

Heudel, Pierre-Etienne ^{[3
]}

Fraisse, Julien ^{[1
]}

Gourgou, Sophie ^{[1
]}

Guiu, Severine ^{[1
,2
]}

Dalenc, Florence ^{[4
]}

Pistilli, Barbara ^{[5
]}

Campone, Mario ^{[6
]}

Levy, Christelle ^{[7
]}

Debled, Marc ^{[8
]}

Leheurteur, Marianne ^{[9
]}

Chaix, Marie ^{[10
]}

Lefeuvre, Claudia ^{[11
]}

Goncalves, Anthony ^{[12
]}

Uwer, Lionel ^{[13
]}

Ferrero, Jean-Marc ^{[14
]}

Eymard, Jean-Christophe ^{[15
]}

Petit, Thierry ^{[16
]}

Mouret-Reynier, Marie-Ange ^{[17
]}

Courtinard, Coralie ^{[18
]}

Cottu, Paul ^{[19
]}

Robain, Mathieu ^{[18
]}

Mailliez, Audrey ^{[20
]}

机构：

[1] Montpellier Univ, Inst Canc Montpellier ICM Val dAurelle, Montpellier, France

[2] IRCM INSERM U1194, Montpellier, France

[3] Ctr Leon Berard, Lyon, France

[4] Inst Claudius Regaud, IUCT Oncopole, Toulouse, France

[5] Gustave Roussy, Villejuif, France

[6] Inst Cancerol Ouest, St Herblain, France

[7] Ctr Francois Baclesse, Caen, France

[8] Inst Bergonie, Bordeaux, France

[9] Ctr Henri Becquerel, Rouen, France

[10] Ctr Georges Francois Leclerc, Dijon, France

[11] Ctr Eugene Marquis, Rennes, France

[12] Inst Paoli Calmettes, Marseille, France

[13] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France

[14] Ctr Antoine Lacassagne, Nice, France

[15] Inst Cancerol Jean Godinot, Reims, France

[16] Ctr Paul Strauss, Strasbourg, France

[17] Ctr Jean Perrin, Clermont Ferrand, France

[18] UNICANCER, Paris, France

[19] Etab Hosp Inst Curie, Paris, France

[20] Ctr Oscar Lambret, Lille, France

来源：

INTERNATIONAL JOURNAL OF CANCER | 2019年 / 145卷 / 12期

关键词：

metastatic breast cancer; eribulin; real-life cohort; PROGRESSION-FREE SURVIVAL; OPEN-LABEL; 1ST-LINE TREATMENT; LOCALLY RECURRENT; PLUS TRASTUZUMAB; SINGLE-ARM; PHASE-II; CHEMOTHERAPY; COMBINATION; THERAPY;

D O I：

10.1002/ijc.32402

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Eribulin mesylate (EM) was recently approved for metastatic breast cancer (MBC) chemotherapy (CT) in late lines by the FDA, with debated results in second line. We evaluated outcomes in breast cancer patients receiving EM as second, third and fourth line in a national real-life cohort of 16,703 consecutive MBC patients initiating their first metastatic therapeutic line between 2008 and 2014. Primary and secondary objectives were overall survival (OS) and progression-free survival (PFS). An imbalance was seen for HER2+ tumors and concomitant anti-HER2 targeted therapies use, we thus performed a subanalysis in HER2- patients. PFS and OS were significantly better in EM patients in third and fourth lines, compared to "Other chemotherapies" patients (PFS: 4.14 vs. 3.02 months, p = 0.0010; 3.61 vs. 2.53 months, p = 0.0102, third and fourth-line; OS: 11.27 vs. 7.65 months, p = 0.0001; 10.91 vs. 5.95 months, p < 0.0001, third and fourth-line). No significant difference was reported in second-line (PFS: 5.06 vs. 4.14 months, p = 0.1171; OS: 13.99 vs. 11.66 months, p = 0.151). Among HER2- patients, a significant difference was seen for all lines, including 2nd-line (PFS: 4.57 vs. 3.91 months, p = 0.0379; OS: 14.98 vs. 10.51 months, p = 0.0113). In this large real-world database, HER2-negative MBC patients receiving EM in second or later CT line presented significantly better PFS and OS. This difference disappeared in second line in the overall population, probably because of the imbalance in HER2-targeted treatments use. Our results mirror those of the published randomized trials. The effect of anti-HER2 therapies addition in this setting still needs to be defined.

引用

页码：3359 / 3369

页数：11

共 30 条

[1] Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis [J].

Adunlin, George ;

Cyrus, John W. W. ;

Dranitsaris, George .

BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (03) :591-608

[2] First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer [J].

Araki, Kazuhiro ;

Fukada, Ippei ;

Yanagi, Hiroyo ;

Kobayashi, Kokoro ;

Shibayama, Tomoko ;

Horii, Rie ;

Takahashi, Shunji ;

Akiyama, Futoshi ;

Ohno, Shinji ;

Ito, Yoshinori .

BREAST, 2017, 35 :78-84

[3] Review on the clinical use of eribulin mesylate for the treatment of breast cancer [J].

Aseyev, Olexiy ;

Ribeiro, Joana M. ;

Cardoso, Fatima .

EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (04) :589-600

[4] Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study [J].

Barni, Sandro ;

Livraghi, Luca ;

Morritti, Maria ;

Vici, Patrizia ;

Michelotti, Andrea ;

Cinieri, Saverio ;

Fontanella, Caterina ;

Porcu, Luca ;

Del Mastro, Lucia ;

Puglisi, Fabio .

FUTURE ONCOLOGY, 2019, 15 (01) :3247-3258

[5] 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) [J].

Cardoso, F. ;

Senkus, E. ;

Costa, A. ;

Papadopoulos, E. ;

Aapro, M. ;

Andre, F. ;

Harbeck, N. ;

Aguilar Lopez, B. ;

Barrios, C. H. ;

Bergh, J. ;

Biganzoli, L. ;

Boers-Doers, C. B. ;

Cardoso, M. J. ;

Carey, L. A. ;

Cortes, J. ;

Curigliano, G. ;

Dieras, V. ;

El Saghir, N. S. ;

Eniu, A. ;

Fallowfield, L. ;

Francis, P. A. ;

Gelmon, K. ;

Johnston, S. R. D. ;

Kaufmann, B. ;

Koppikar, S. ;

Krop, I. E. ;

Mayer, M. ;

Nakigudde, G. ;

Offersen, B. V. ;

Ohno, S. ;

Pagani, O. ;

Paluch-Shimon, S. ;

Penault-Llorca, F. ;

Prat, A. ;

Rugo, H. S. ;

Sledge, G. W. ;

Spence, D. ;

Thomssen, C. ;

Vorobiof, D. A. ;

Xu, B. ;

Norton, L. ;

Winer, E. P. .

ANNALS OF ONCOLOGY, 2018, 29 (08) :1634-1657

[6] 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (vol 28, pg 16, 2016) [J].

Cardoso, F. ;

Costa, A. ;

Senkus, E. ;

Aapro, M. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Bhattacharyya, G. ;

Biganzoli, L. ;

Cardoso, M. J. ;

Carey, L. ;

Corneliussen-James, D. ;

Curigliano, G. ;

Dieras, V. ;

El Saghir, N. ;

Eniu, A. ;

Fallowfield, L. ;

Fenech, D. ;

Francis, P. ;

Gelmon, K. ;

Gennari, A. ;

Harbeck, N. ;

Hudis, C. ;

Kaufman, B. ;

Krop, I. ;

Mayer, M. ;

Meijer, H. ;

Mertz, S. ;

Ohno, S. ;

Pagani, O. ;

Papadopoulos, E. ;

Peccatori, F. ;

Penault-Llorca, F. ;

Piccart, M. J. ;

Pierga, J. Y. ;

Rugo, H. ;

Shockney, L. ;

Sledge, G. ;

Swain, S. ;

Thomssen, C. ;

Tutt, A. ;

Vorobiof, D. ;

Xu, B. ;

Norton, L. ;

Winer, E. .

ANNALS OF ONCOLOGY, 2017, 28 (12) :3111-3111

[7] Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study [J].

Cortes, Javier ;

O'Shaughnessy, Joyce ;

Loesch, David ;

Blum, Joanne L. ;

Vahdat, Linda T. ;

Petrakova, Katarina ;

Chollet, Philippe ;

Manikas, Alexey ;

Dieras, Veronique ;

Delozier, Thierry ;

Vladimirov, Vladimir ;

Cardoso, Fatima ;

Koh, Han ;

Bougnoux, Philippe ;

Dutcus, Corina E. ;

Seegobin, Seth ;

Mir, Denis ;

Meneses, Nicole ;

Wanders, Jantien ;

Twelves, Chris .

LANCET, 2011, 377 (9769) :914-923

[8]

COX DR, 1972, J R STAT SOC B, V34, P187

[9] Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study [J].

Delaloge, S. ;

Perol, D. ;

Courtinard, C. ;

Brain, E. ;

Asselain, B. ;

Bachelot, T. ;

Debled, M. ;

Dieras, V. ;

Campone, M. ;

Levy, C. ;

Jacot, W. ;

Lorgis, V. ;

Veyret, C. ;

Dalenc, F. ;

Ferrero, J. M. ;

Uwer, L. ;

Kerbrat, P. ;

Goncalves, A. ;

Mouret-Reynier, M. A. ;

Petit, T. ;

Jouannaud, C. ;

Vanlemmens, L. ;

Chenuc, G. ;

Guesmia, T. ;

Robain, M. ;

Cailliot, C. .

ANNALS OF ONCOLOGY, 2016, 27 (09) :1725-1732

[10] Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study [J].

Dell'Ova, Melodie ;

De Maio, Eleonora ;

Guiu, Severine ;

Roca, Lise ;

Dalenc, Florence ;

Durigova, Anna ;

Pinguet, Frederic ;

Bekhtari, Khedidja ;

Jacot, William ;

Pouderoux, Stephane .

BMC CANCER, 2015, 15

← 1 2 3 →